7575
Japan Lifeline Co., Ltd.
日本ライフライン株式会社Japan Lifeline Co., Ltd., a medical device company, engages in manufacturing and sale of medical device in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, disposable ECG recorder, and venous vascular closure system. Its cardiovascular and endografting products consist of vascular and open stent grafts, and abdominal stent-grafts, as well as embolic coil deploying systems. In addition, the company offers gastrointestinal intervention products, including cholangioscope, biliary tube stent, papillary balloon dilatation catheter, self-expandable duodenal and colonic stent, endoscopic guidewire, and radiofrequency ablation systems; structural heart disease intervention products, such as radiofrequency wires and atrial septal defect closure devices; and aspiration catheter neurovascular intervention product. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.
Price
¥1,327
Market Cap
¥93.2B
Ent. Value
¥83.6B
Net Cash
¥9.6B
Shares Out.
70.2M
P / E
10.0×
EV / EBIT
6.6×
P / Book
1.41×
P / NCAV
2.68×
Div. Yield
4.07%
Financials
| Metric |
FY 2025
TDnet |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Net Sales | ¥59.2B | ¥56.6B | ¥51.4B | ¥51.8B | ¥51.5B |
| Cost of Sales | ¥24.0B | ¥22.4B | ¥20.4B | ¥21.9B | ¥22.6B |
| Gross Profit | ¥35.2B | ¥34.2B | ¥31.0B | ¥29.9B | ¥28.8B |
| SG&A | ¥22.6B | ¥21.9B | ¥20.1B | ¥19.1B | ¥18.9B |
| Operating Income | ¥12.6B | ¥12.3B | ¥10.9B | ¥10.8B | ¥10.0B |
| Non-Operating Income | ¥392M | ¥336M | ¥390M | ¥293M | ¥316M |
| Dividend Income | — | ¥57M | ¥52M | ¥76M | ¥47M |
| Interest Income | — | ¥196M | ¥156M | ¥105M | ¥63M |
| Non-Operating Expenses | — | ¥327M | ¥701M | ¥224M | ¥285M |
| Interest Expense | — | ¥36M | ¥26M | ¥34M | ¥76M |
| Ordinary Income | ¥12.6B | ¥12.3B | ¥10.6B | ¥10.9B | ¥10.0B |
| Pre-tax Income | ¥12.4B | ¥12.0B | ¥10.6B | ¥9.8B | ¥10.0B |
| Income Taxes | ¥3.0B | ¥2.7B | ¥3.1B | ¥2.9B | ¥2.6B |
| Current Tax | — | ¥3.0B | ¥3.1B | ¥2.9B | ¥2.9B |
| Deferred Tax | — | ¥-315M | ¥-22M | ¥-2M | ¥-347M |
| Net Income (owners) | ¥9.3B | ¥9.3B | ¥7.5B | ¥6.9B | ¥7.5B |
| Comprehensive Income | — | ¥10.0B | ¥8.2B | ¥6.6B | ¥7.7B |
| EBITDA | ¥14.3B | ¥14.1B | ¥12.4B | ¥12.4B | ¥11.6B |
| EPS | ¥133.30 | ¥131.43 | ¥98.73 | ¥88.22 | ¥93.13 |
| Shares Outstanding | — | 70.2M | 75.1M | 78.0M | 80.0M |
| Shares Issued (total) | — | 75.8M | 75.8M | 82.9M | 85.4M |
| Treasury Shares | — | 5.5M | 0.7M | 4.9M | 5.4M |